Trial Profile

A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Capecitabine; Fluorouracil; Mitomycin
Indications Bladder cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms Indi-Blade

01 Apr 2026 Primary endpoint (Efficacy defined as bladder-intact event-free survival (BI-EFS)) has been met, according to results published in Nature Medicine.
01 Apr 2026 Results aimed to provide effective bladder-sparing treatment to patients with stage II/III (cT2-4aN0-2, n = 50) MIBC, using induction ipilimumab (3 mg kg-1) plus nivolumab followed by CRT were published in the Nature Medicine.
15 Mar 2024 Planned End Date changed from 1 Dec 2027 to 5 Sep 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com